Author Archives: Olivier

Ariana Pharma announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies

Ariana® Pharma a leading Artificial Intelligence drug development company announced on April 29th that it [...]

Vertex Forges Gene Therapy Collaboration With Obsidian, bluebird Stumbles in Germany

After doubling down on its gene editing collaboration with CRISPR Therapeutics, Vertex Pharmaceuticals and Obsidian [...]

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe [...]

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi announced on April 09th that it has acquired Tidal Therapeutics, a privately owned, pre-clinical [...]

Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Pharma has experienced a string of changes over the past year, coming to a head [...]

FDA approves first CAR-T cell therapy for multiple myeloma

The Food and Drug Administration approved on March 02nd the first CAR-T cell therapy for [...]

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec SE announced on March 22nd that the Company has entered into a multi-RNA target [...]

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for [...]

ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene [...]

New Report Finds Medical Treatments for Rare Diseases Account for Only 11% of US Drug Spending; Nearly 80% of Orphan Products Treat Rare Diseases Exclusively

As US policymakers consider options to address rising health care costs while still meeting the needs [...]